UBS Group
KROS icon

UBS Group’s Keros Therapeutics KROS Stock Holding History

UBS Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.61M Buy
145,573
+48,489
+50% +$749K ﹤0.01% 5165
2025
Q4 		$1.98M Sell
97,084
-6,780
-7% -$119K ﹤0.01% 4994
2025
Q3 		$1.64M Buy
103,864
+1,091
+1% +$16.1K ﹤0.01% 5145
2025
Q2 		$1.37M Buy
102,773
+10,344
+11% +$140K ﹤0.01% 5166
2025
Q1 		$942K Sell
92,429
-82,512
-47% -$958K ﹤0.01% 5327
2024
Q4 		$2.77M Buy
174,941
+119,034
+213% +$6.19M ﹤0.01% 4408
2024
Q3 		$3.25M Sell
55,907
-9,648
-15% -$476K ﹤0.01% 3511
2024
Q2 		$3M Sell
65,555
-58,630
-47% -$3.15M ﹤0.01% 3350
2024
Q1 		$8.22M Sell
124,185
-57,200
-32% -$3.39M ﹤0.01% 2451
2023
Q4 		$7.21M Buy
181,385
+174,798
+2,654% +$5.48M ﹤0.01% 2381
2023
Q3 		$210K Sell
6,587
-23,129
-78% -$863K ﹤0.01% 5337
2023
Q2 		$1.19M Sell
29,716
-3,335
-10% -$146K ﹤0.01% 4069
2023
Q1 		$1.41M Sell
33,051
-16,128
-33% -$815K ﹤0.01% 3781
2022
Q4 		$2.36M Sell
49,179
-114,060
-70% -$5.33M ﹤0.01% 3235
2022
Q3 		$6.14M Sell
163,239
-33,676
-17% -$1.17M ﹤0.01% 2173
2022
Q2 		$5.44M Sell
196,915
-2,768
-1% -$121K ﹤0.01% 2304
2022
Q1 		$10.9M Buy
199,683
+44,068
+28% +$2.26M ﹤0.01% 1878
2021
Q4 		$9.11M Buy
155,615
+25,833
+20% +$1.29M ﹤0.01% 2226
2021
Q3 		$5.13M Buy
129,782
+128,362
+9,040% +$4.57M ﹤0.01% 2642
2021
Q2 		$60K Sell
1,420
-14,147
-91% -$766K ﹤0.01% 6271
2021
Q1 		$958K Buy
15,567
+15,318
+6,152% +$970K ﹤0.01% 4303
2020
Q4 		$18K Buy
+249
New +$15.7K ﹤0.01% 7013
2020
Q3 		– Sell
-2,207
Closed -$83K – 8227
2020
Q2 		$83K Buy
+2,207
New +$68K ﹤0.01% 5443

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

UBS Group's KROS Position: Q1 2026 in Review

UBS Group increased its Keros Therapeutics (KROS) stake by 50% in Q1 2026, buying an estimated $749K and bringing the position to 145,573 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #5165.

UBS Group first reported a position in KROS in Q2 2020 and has held it in 23 quarters since. The position peaked at $10.9M in Q1 2022. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • UBS Group held 145,573 shares of Keros Therapeutics worth $1.61M as of Q1 2026.
  • UBS Group bought 48,489 Keros Therapeutics shares in Q1 2026, an estimated $749K.
  • Keros Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5165 holding.
  • UBS Group first reported a position in Keros Therapeutics in Q2 2020 and has held it in 23 quarters since.
  • UBS Group's Keros Therapeutics position peaked at $10.9M in Q1 2022.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.